Abstract
Diabetic dyslipidaemia refers to the triad of elevated levels of triglycerides and small, dense LDL-C particles and low levels of HDL-C. These lipid abnormalities are largely responsible for the increased risk of cardiovascular complications in patients with diabetes. This case study outlines a rational approach to the treatment of each of these lipid abnormalities and emphasises the importance of both lowering the LDL-C and raising the HDL-C in high-risk individuals. Combination drug therapy will often be necessary to achieve treatment goals in these patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 25-30 |
| Number of pages | 6 |
| Journal | British Journal of Diabetes and Vascular Disease |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2007 |
Fingerprint
Keywords
- Atherogenic dyslipidaemia
- Diabetes
- Diabetic dyslipidaemia
- Fibrates
- Niacin
- Statins
ASJC Scopus subject areas
- Internal Medicine
- Cardiology and Cardiovascular Medicine
- Endocrinology, Diabetes and Metabolism
Cite this
Rational therapy of mixed dyslipidaemia in a patient with diabetes. / Reasner, Charles.
In: British Journal of Diabetes and Vascular Disease, Vol. 7, No. 1, 01.2007, p. 25-30.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rational therapy of mixed dyslipidaemia in a patient with diabetes
AU - Reasner, Charles
PY - 2007/1
Y1 - 2007/1
N2 - Diabetic dyslipidaemia refers to the triad of elevated levels of triglycerides and small, dense LDL-C particles and low levels of HDL-C. These lipid abnormalities are largely responsible for the increased risk of cardiovascular complications in patients with diabetes. This case study outlines a rational approach to the treatment of each of these lipid abnormalities and emphasises the importance of both lowering the LDL-C and raising the HDL-C in high-risk individuals. Combination drug therapy will often be necessary to achieve treatment goals in these patients.
AB - Diabetic dyslipidaemia refers to the triad of elevated levels of triglycerides and small, dense LDL-C particles and low levels of HDL-C. These lipid abnormalities are largely responsible for the increased risk of cardiovascular complications in patients with diabetes. This case study outlines a rational approach to the treatment of each of these lipid abnormalities and emphasises the importance of both lowering the LDL-C and raising the HDL-C in high-risk individuals. Combination drug therapy will often be necessary to achieve treatment goals in these patients.
KW - Atherogenic dyslipidaemia
KW - Diabetes
KW - Diabetic dyslipidaemia
KW - Fibrates
KW - Niacin
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=33947215569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947215569&partnerID=8YFLogxK
U2 - 10.1177/14746514070070010501
DO - 10.1177/14746514070070010501
M3 - Article
AN - SCOPUS:33947215569
VL - 7
SP - 25
EP - 30
JO - British Journal of Diabetes and Vascular Disease
JF - British Journal of Diabetes and Vascular Disease
SN - 1474-6514
IS - 1
ER -